Summary & Overview
CPT 80356: Heroin Metabolite Detection in Patient Specimen
CPT code 80356 represents a laboratory toxicology test that measures or detects the presence of a heroin metabolite in a patient specimen. This code is used to document and bill for biochemical confirmation of heroin exposure, an important component of clinical care, forensic investigations, substance use disorder management, and public health surveillance. Nationally, toxicology testing for opioids including heroin remains clinically and operationally significant given ongoing substance use and overdose trends.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication provides a national perspective on coverage and billing contexts for this test across major commercial and federal payers.
Readers will learn the clinical context for ordering heroin metabolite testing, typical sites of service where the test is performed, common billing modifiers that may be applied (listed separately), and which payers are included in the coverage review. The report also outlines what benchmarking and policy topics are relevant for this code, including coding accuracy, laboratory reporting practices, and payer-specific coverage considerations. Data not available in the input is noted where applicable.
Billing Code Overview
CPT code 80356 describes a laboratory test in which a lab analyst measures the amount of or detects the presence of a heroin metabolite in a patient specimen. This service is a toxicology/drug testing procedure used to identify exposure to or use of heroin through biochemical analysis of biological samples.
Service Type: Laboratory toxicology testing
Typical Site of Service: Clinical laboratory, hospital laboratory, or outpatient specimen collection site
Clinical & Coding Specifications
Clinical Context
A 28-year-old adult presents to an outpatient substance use clinic for initial intake and urine drug testing as part of a suspected heroin use evaluation and monitoring program. The clinician orders a urine or serum toxicology panel with specific confirmation testing for heroin metabolites (6-monoacetylmorphine or morphine) to confirm recent heroin exposure. The specimen is collected under chain-of-custody procedures if results will support legal, occupational, or treatment-program decisions. The specimen is received by the clinical laboratory, accessioned, and analyzed by a qualified lab analyst using presumptive immunoassay screening followed by confirmatory testing (e.g., gas chromatography–mass spectrometry or liquid chromatography–tandem mass spectrometry) to measure the amount of or detect the presence of heroin metabolites. Results are reported to the ordering provider and integrated into the patient’s treatment plan, with documentation of test method, analytic limits, and specimen collection details in the medical record.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when billing only the professional interpretation component and the lab code is split between technical and professional components. |
52 |